Clinical data | |
---|---|
Trade names | Elocta, Eloctate |
Other names | Antihemophilic Factor (Recombinant), FcFusion Protein |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Antihemorrhagic |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C9736H14863N2591O2855S78 |
Molar mass | 216390.96 g·mol−1 |
Efmoroctocog alfa, sold under the brand name Elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. [5] [6] [7] Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc). [5] It is produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line. [5] [6]
It was approved for medical use in the United States in June 2014, [8] and for use in the European Union in November 2015. [6]
In the United States, efmoroctocog alfa (Eloctate) is indicated for adults and children with Hemophilia A for (1) on-demand treatment and control of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes. [9] [5]
In the European Union, efmoroctocog alfa (Elocta) is indicated for treatment and prophylaxis of bleeding in people with haemophilia A. [6]
{{
cite web}}
: CS1 maint: archived copy as title (
link)
Clinical data | |
---|---|
Trade names | Elocta, Eloctate |
Other names | Antihemophilic Factor (Recombinant), FcFusion Protein |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Antihemorrhagic |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C9736H14863N2591O2855S78 |
Molar mass | 216390.96 g·mol−1 |
Efmoroctocog alfa, sold under the brand name Elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. [5] [6] [7] Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc). [5] It is produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line. [5] [6]
It was approved for medical use in the United States in June 2014, [8] and for use in the European Union in November 2015. [6]
In the United States, efmoroctocog alfa (Eloctate) is indicated for adults and children with Hemophilia A for (1) on-demand treatment and control of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes. [9] [5]
In the European Union, efmoroctocog alfa (Elocta) is indicated for treatment and prophylaxis of bleeding in people with haemophilia A. [6]
{{
cite web}}
: CS1 maint: archived copy as title (
link)